MA54755A - Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4 - Google Patents

Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4

Info

Publication number
MA54755A
MA54755A MA054755A MA54755A MA54755A MA 54755 A MA54755 A MA 54755A MA 054755 A MA054755 A MA 054755A MA 54755 A MA54755 A MA 54755A MA 54755 A MA54755 A MA 54755A
Authority
MA
Morocco
Prior art keywords
imidazo
irak4 inhibitors
pyridinyl derivatives
pyridinyl
derivatives
Prior art date
Application number
MA054755A
Other languages
English (en)
Inventor
Philippe Bolduc
Istvan Enyedy
Ryan Evans
Fang Gao
Brian T Hopkins
Tricia May-Dracka
Emily Anne Peterson
Magnus Pfaffenbach
Zhili Xin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA54755A publication Critical patent/MA54755A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054755A 2019-01-18 2020-01-17 Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4 MA54755A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962794098P 2019-01-18 2019-01-18

Publications (1)

Publication Number Publication Date
MA54755A true MA54755A (fr) 2021-11-24

Family

ID=69724065

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054755A MA54755A (fr) 2019-01-18 2020-01-17 Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4

Country Status (5)

Country Link
US (1) US20220089592A1 (fr)
EP (1) EP3911652A1 (fr)
JP (1) JP7576552B2 (fr)
MA (1) MA54755A (fr)
WO (1) WO2020150626A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
US20220227758A1 (en) * 2019-06-26 2022-07-21 Medshine Discovery Inc. Imidazopyridine compound as irak4 inhibitor
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (fr) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
EP4072591A4 (fr) 2019-12-10 2024-06-05 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
IL303966A (en) * 2020-12-22 2023-08-01 Biogen Ma Inc The history of imidazo[2,1-A]pyridine as IRAK4 inhibitors and their use in the treatment of diseases
MX2023007510A (es) * 2020-12-22 2023-09-08 Biogen Ma Inc Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades.
EP4269409A4 (fr) * 2020-12-25 2024-12-11 Medshine Discovery Inc. Composé amide d'oxazole
WO2022147465A1 (fr) 2020-12-30 2022-07-07 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
CN112724079A (zh) * 2021-02-04 2021-04-30 康化（上海）新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
JP2024525580A (ja) * 2021-07-07 2024-07-12 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
TW202330546A (zh) * 2021-12-31 2023-08-01 香港商愛科諾生物醫藥(香港)有限公司 具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用
WO2024020522A1 (fr) * 2022-07-22 2024-01-25 Arvinas Operations, Inc. Composés et procédés pour la dégradation ciblée d'irak-4
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024067845A1 (fr) * 2022-09-29 2024-04-04 武汉人福创新药物研发中心有限公司 Composé imidazopyridine utilisé en tant qu'agent de dégradation d'irak4 et son utilisation
EP4638447A1 (fr) * 2022-12-21 2025-10-29 Dark Blue Therapeutics Ltd Dérivés imidazo[1,2-a]pyridines et imidazo[1,2-a]pyrazines en tant qu'inhibiteurs de mllt1 et mllt3
EP4389747A1 (fr) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Composés imidazo[1,2-a]pyridiniques et imidazo[1,2-a]pyraziniques en tant qu'inhibiteurs de mllt1 et mllt3
CN115959976A (zh) * 2022-12-30 2023-04-14 安徽诺全药业有限公司 一种甲氧基取代双环戊烷衍生物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7909801A (en) * 2000-08-01 2002-02-13 Sod Conseils Rech Applic Imidazolyl derivatives
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
AU2004265189B2 (en) 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2011036461A1 (fr) * 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncόlogicas (Cnio) Imidazo [3, 2 - d] pyrazines fusionnées utilisées en tant qu'inhibiteurs de la kinase pi3
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2013042137A1 (fr) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Hétérocycles bicycliques convenant comme inhibiteurs de l'irak4
AR096684A1 (es) 2013-06-25 2016-01-27 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SMT202400142T1 (it) * 2014-01-13 2024-05-14 Aurigene Oncology Ltd Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
JP6675334B2 (ja) 2014-06-25 2020-04-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR119234A1 (es) * 2019-06-27 2021-12-01 Biogen Ma Inc Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades

Also Published As

Publication number Publication date
WO2020150626A1 (fr) 2020-07-23
JP2022517410A (ja) 2022-03-08
JP7576552B2 (ja) 2024-10-31
EP3911652A1 (fr) 2021-11-24
US20220089592A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
PL3873900T3 (pl) Imidazo[1,2-a]pirydynowe pochodne jako inhibitory integryny alpha4beta7 do leczenia chorób zapalnych
IL312020A (en) Imidazo[1,2-a]pyridine derivatives
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
DK2118101T3 (da) IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
HUE051424T2 (hu) RET kináz inhibitor szubsztituált pirazolo[1,5-a]piridin vegyületek
IL285311A (en) Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
DK3959211T3 (da) 4h-pyrrol[3,2-c]pyridin-4-on-forbindelser
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
DK3611174T3 (da) [1,2,4]triazolo[1,5-c]pyrimidinderivat som a2a-receptorinhibitor
DK1904494T3 (da) Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer
EP3481827A4 (fr) Dérivés d'imidazo[1,2-a]pyridine, leurs procédés de préparation et leur utilisation
DK2124944T3 (da) Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
MEP23808A (en) Pyridine[3,4-b]pyrazinones
HK1247203A1 (zh) 取代的咪唑并[1，2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
MA43020A (fr) Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles
DK3840832T3 (da) Imidazo[1,2-b]pyridaziner som trk-inhibitorer
IL269214B (en) Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
WO2015171526A3 (fr) Composés de pyrazolopyridine tricycliques
PL3952995T3 (pl) Pochodne bicyklicznych heteroaryli jako inhibitory ekto- pirofosfatazy/fosfodiesterazy nukleotydowej 1
EP3679042A4 (fr) Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
EP3551630A4 (fr) Dérivés d'imidazo [1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
MA55593A (fr) Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1
MA51285A (fr) Dérivés d'azaindole comme inhibiteurs de rho-kinase
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors